Novartis Reveals Pharma Leadership Changes Amid Business Transition
This article was originally published in The Pink Sheet Daily
Novartis announced Vas Narasimhan will be global head of development for Novartis’ pharma unit, and Rainer Boehm will be chief commercial officer of general medicines.
You may also be interested in...
Novartis had a busy second quarter with Diovan in the news and a major deal with GSK that portends an evolving focus in emerging markets.
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.